✦ LIBER ✦

Treatment of classic Kaposi sarcoma with a nicotine dermal patch: a phase II clinical trial

✍ Scribed by JJ Goedert; BM Scoppio; R Pfeiffer; L Neve; AB Federici; LR Long; BM Dolan; M Brambati; M Bellinvia; C Lauria; L Preiss; V Boneschi; D Whitby; L Brambilla

Book ID: 111095568
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 172 KB
Volume: 22
Category: Article
ISSN: 0926-9959
DOI: 10.1111/j.1468-3083.2008.02720.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Electrochemotherapy in the Treatment of

Electrochemotherapy in the Treatment of Kaposi Sarcoma Cutaneous Lesions: A Two-Center Prospective Phase II Trial

✍ Pietro Curatolo; Pietro Quaglino; Federica Marenco; Monica Mancini; Tiziana Nard 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 377 KB

Treatment of intraoral ranulas with micr

Treatment of intraoral ranulas with micromarsupialization: Clinical outcomes and safety from a phase II clinical trial

✍ Woo, Seung Hoon; Chi, Jun Hyuk; Kim, Bo Hae; Kwon, Seong Keun 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 308 KB

Treatment of systemic sclerosis with rec

Treatment of systemic sclerosis with recombinant interferon-γ. A phase I/II clinical trial

✍ Bruce Freundlich; Sergio A. Jimenez; Virginia D. Steen; Thomas A. Medsger Jr.; M 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 839 KB

Imiquimod 5% cream for treatment of HIV-

Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients

✍ Noël Emile Célestin Schartz; Sylvie Chevret; Carolina Paz; Delphine Kerob; Olivi 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 447 KB

Oral etoposide as first-line therapy in

Oral etoposide as first-line therapy in the treatment of patients with advanced classic Kaposi’s sarcoma (CKS): a single-arm trial (oral etoposide in CKS)

✍ F. Tas; F. Sen; S. Keskin; L. Kilic 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB

Results of a phase-II clinical trial on

Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma

✍ E. M. Lemmel; M. Franke; W. Gaus; P. W. Hartl; P. H. Hofschneider; K. Miehlke; K 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 552 KB

In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 micrograms; in the se